SBH
FATE icon

Segall Bryant & Hamill’s Fate Therapeutics FATE Stock Holding History

Segall Bryant & Hamill’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-164,235
Closed -$1.66M – 727
2022
Q4 		$1.66M Buy
164,235
+11,184
+7% +$210K 0.02% 437
2022
Q3 		$3.43M Buy
153,051
+3,038
+2% +$87.8K 0.04% 365
2022
Q2 		$3.72M Buy
150,013
+44,513
+42% +$1.23M 0.04% 367
2022
Q1 		$4.09M Buy
105,500
+246
+0.2% +$9.53K 0.04% 355
2021
Q4 		$6.16M Buy
105,254
+4,950
+5% +$281K 0.06% 290
2021
Q3 		$5.95M Buy
100,304
+38,091
+61% +$2.99M 0.06% 293
2021
Q2 		$5.4M Buy
62,213
+3,325
+6% +$268K 0.05% 313
2021
Q1 		$4.85M Sell
58,888
-11,151
-16% -$1.07M 0.05% 339
2020
Q4 		$6.37M Sell
70,039
-1,299
-2% -$80.7K 0.07% 252
2020
Q3 		$2.85M Buy
71,338
+51,741
+264% +$1.81M 0.04% 346
2020
Q2 		$672K Buy
+19,597
New +$584K 0.01% 526

Other funds holding FATE

State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Segall Bryant & Hamill's FATE Position: Q1 2023 in Review

Segall Bryant & Hamill sold out of Fate Therapeutics (FATE) in Q1 2023, closing a stake of 164,235 shares — an estimated $1.66M sold.

Segall Bryant & Hamill first reported a position in FATE in Q2 2020 and held it in 11 quarters. The position peaked at $6.37M in Q4 2020. 181 funds tracked by Wall St. Rank hold FATE as of Q1 2023.

  • Segall Bryant & Hamill reported no remaining Fate Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Segall Bryant & Hamill sold 164,235 Fate Therapeutics shares in Q1 2023, an estimated $1.66M.
  • Segall Bryant & Hamill first reported a position in Fate Therapeutics in Q2 2020 and held it in 11 quarters.
  • Segall Bryant & Hamill's Fate Therapeutics position peaked at $6.37M in Q4 2020.
  • 181 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2023.

Based on Segall Bryant & Hamill's 13F filing for Q1 2023, filed 15 May 2023.